UY35545A - Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación - Google Patents

Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación

Info

Publication number
UY35545A
UY35545A UY0001035545A UY35545A UY35545A UY 35545 A UY35545 A UY 35545A UY 0001035545 A UY0001035545 A UY 0001035545A UY 35545 A UY35545 A UY 35545A UY 35545 A UY35545 A UY 35545A
Authority
UY
Uruguay
Prior art keywords
procedures
coag
ulation
compositions
factory
Prior art date
Application number
UY0001035545A
Other languages
English (en)
Inventor
Aswad Fred
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35545A publication Critical patent/UY35545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan conjugados para inducir tolerancia de la proteína factor de coagulación, en el que el conjugado comprende una proteína factor de coagulación o un fragmento antigénico o variante del mismo y un ligando Siglec. También se proporcionan composiciones farmaceúticas, procedimientos y kits que comprenden los conjugados.
UY0001035545A 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación UY35545A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361816790P 2013-04-28 2013-04-28

Publications (1)

Publication Number Publication Date
UY35545A true UY35545A (es) 2014-11-28

Family

ID=50846907

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035545A UY35545A (es) 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación

Country Status (11)

Country Link
US (1) US20160279252A1 (es)
EP (1) EP2991684B1 (es)
JP (1) JP2016519120A (es)
CN (1) CN105451774A (es)
AR (1) AR096123A1 (es)
CA (1) CA2910277A1 (es)
ES (1) ES2691041T3 (es)
HK (1) HK1217167A1 (es)
TW (1) TW201519900A (es)
UY (1) UY35545A (es)
WO (1) WO2014179184A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060324A1 (en) * 2013-04-22 2016-03-03 James C. Paulson Methods and Compositions for Treating Bleeding Disorders
EP3458085B1 (en) * 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
CN108926719B (zh) * 2017-05-25 2020-09-01 北京格瑞特森生物医药科技有限公司 用c(RGD-ACP-K)修饰的长循环脂质体
WO2018225873A1 (ja) * 2017-06-09 2018-12-13 協和発酵キリン株式会社 核酸含有ナノ粒子
EP3839059A1 (en) * 2019-12-16 2021-06-23 CGT Enterprises, LLC Devices and methods for determining coagulation factor activities
WO2024015872A2 (en) * 2022-07-13 2024-01-18 Osprey Biopharmaceuticals, Inc. Autoantigens engineered to suppress autoimmune response
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055946A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP4738346B2 (ja) * 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
PL1824988T3 (pl) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
JP2009511082A (ja) * 2005-10-17 2009-03-19 ヘルス リサーチ インコーポレイテッド 糖類のためのトランスフェラーゼに特異的な受容体並びにその入手及び使用方法
EP2461821A4 (en) * 2009-07-31 2013-07-03 Bayer Healthcare Llc MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF

Also Published As

Publication number Publication date
AR096123A1 (es) 2015-12-09
JP2016519120A (ja) 2016-06-30
EP2991684B1 (en) 2018-07-11
EP2991684A1 (en) 2016-03-09
HK1217167A1 (zh) 2016-12-30
US20160279252A1 (en) 2016-09-29
CN105451774A (zh) 2016-03-30
WO2014179184A1 (en) 2014-11-06
TW201519900A (zh) 2015-06-01
CA2910277A1 (en) 2014-11-06
WO2014179184A8 (en) 2015-10-29
ES2691041T3 (es) 2018-11-23

Similar Documents

Publication Publication Date Title
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA52669A (fr) Conjugués peptidiques de camptothécine
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
UY4235Q (es) Configuración aplicada en zapato
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
BR112015021880A2 (pt) rearranjo de vírus influenza b
BR112016019389A8 (pt) Vacina, e, peptídeo
CO2017007316A2 (es) Formulación farmacéutica
DK3666787T3 (da) Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
UY4314Q (es) Configuracion aplicada en zapato
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
NI201600061A (es) Formulaciones de inyección con base en aceite de sésamo
UY4233Q (es) Configuración aplicada en zapato
CR20150352A (es) Nuevas composiciones antifúngicidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206